For Healthcare Professionals

5 DIFFERENT VEHICLES

Acne, Rosacea, Seborrheic Dermatitis.

Whatever my skin throws at me, my dermatologist has me covered.

THE AVAR^® LINE OF PRODUCTS

The AVAR^® line of products provides safe and effective treatment of seborrheic dermatitis (SD), acne vulgaris (AV), and acne rosacea (AR). AVAR^® products contain sodium sulfacetamide, a sulfonamide antibiotic.

AVAR^® Cleansers

AVAR^® Creams

AVAR-e Green^® Cream

More
vehicles

than other sodium sulfacetamides + sulfur therapies

Powerful efficacy

of the clinically proven ingredients sodium sulfacetamindes + sulfur^1,2

Low
sulfur

option further reduces odor for enhanced patient acceptance^2,3,4

Low odor

across all 5 AVAR formulations^2-7

Promotes peeling

and cell turnover with an effective antibacterial and drying agent²

Steroid free

making it more suitable for chronic therapy^3-7

Suppresses bacteria

associated with acne, rosacea, and seborrheic dermatitis²

AVAR^® CLEANSERS

Deep Cleanse

A gentle, effective cleanser that will not bleach clothing or towels. Suitable for patients 12 years of age or older. Available in traditional (sulfur 5%) and LS (low sulfur, 2%) formulations.^3,5

AVAR® Cleanser Prescribing Information >
AVAR® LS Cleanser Prescribing Information >

AVAR^® CREAMS

Moisturize to the Max

A cosmetically elegant moisturizer that prevents dryness and reduces the redness of rosacea. Available in traditional (sulfur 5%) and LS (low sulfur, 2%) formulations.^1,4,6

AVAR-e® Emollient Cream Prescribing Information >
AVAR-e® LS Emollient Cream Prescribing Information >

AVAR-e GREEN^® CREAM

Get the Red Out

AVAR-e Green^® (sulfur 5%) Emollient Cream includes all the benefits of Avar-e^® Emollient Cream and is specially formulated to reduce the red appearance of rosacea. Contains an odor inhibitor.^1,6,7

AVAR-e Green® Cream Prescribing Information >

References

Sodium sulfacetamide 10%-sulfur 5% (SSS) for the topical treatment of seborrheic dermatitis, acne vulgaris, and rosacea. Poster presented at: 32nd Anniversary Fall Clinical Dermatology Conference; October 17-20, 2013; Las Vegas, NV.
Wolf K, Silapunt S. The use of sodium sulfacetamide in dermatology. Cutis. 2015;96(2):128–130.
AVAR LS Cleanser [package insert]. San Antonio, TX: Mission Pharmacal Company.
AVAR-e LS Emollient Cream [package insert]. San Antonio, TX: Mission Pharmacal Company.
AVAR Cleanser [package insert]. San Antonio, TX: Mission Pharmacal Company.
AVAR-e Emollient Cream [package insert]. San Antonio, TX: Mission Pharmacal Company.
AVAR e-Green Cream [package insert]. San Antonio, TX: Mission Pharmacal Company.

Important Safety Information

CONTRAINDICATIONS: AVAR Cleanser, AVAR LS Cleanser, AVAR-e Emollient Cream, AVAR-e Green Color Corrective Emollient Cream, AVAR-e LS Emollient Cream are contraindicated for use by patients with known or suspected hypersensitivity to sulfonamides, sulfur or any other components of these preparations.

These AVAR brand products should not be used by patients with kidney disease.

WARNINGS: Although rare, sensitivity to sodium sulfacetamide may occur. Patients who may be prone to hypersensitivity to topical sulfonamides should be carefully monitored. Serious hypersensitivity reactions, such as Stevens-Johnson syndrome, have been reported with sulfonamides, including topical sodium sulfacetamide. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide, including one case with a fatal outcome, have been reported. The AVAR brand products should be discontinued at the first signs of hypersensitivity, skin rash, or other reactions.

Systemic toxic reactions (e.g., agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis) indicate sensitivity to sulfonamides. Particular caution should be employed if topical sulfacetamide is applied to large, infected, abraded, denuded or severely burned areas, as any adverse events associated with systemic use may occur, and appropriate observations and laboratory determinations should be performed.

TOPICAL SODIUM SULFACETAMIDE SHOULD BE KEPT OUT OF THE REACH OF CHILDREN.

Nonsusceptible organisms, including fungi, may proliferate with use of these preparations.

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

The AVAR product family is for external use only. Patients should be instructed to avoid contact with eyes, lips, and mucous membranes.

If the condition under treatment becomes worse, or irritation, signs of hypersensitivity, or other untoward reactions occur, these products should be discontinued and appropriate therapy instituted. Patients should be instructed to discontinue these preparations immediately and notify a physician if any arthritis, fever, or sores in the mouth develop.

Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Long-term animal studies to assess carcinogenic potential of these products have not been performed.

There are no adequate and well controlled studies of topical sodium sulfacetamide in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman. These products should be given to a pregnant woman only if clearly needed, or when potential benefits outweigh potential hazards to the fetus.

It is not known whether sodium sulfacetamide is excreted in human milk following topical use. Because many drugs are excreted in human milk, caution should be exercised in prescribing for nursing women.

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

ADVERSE REACTIONS: Reports of local irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported.